PD-L1 IHC 22C3 pharmDx Testing for Esophageal Cancer

In esophageal cancer, PD-L1 testing with PD-L1 IHC 22C3 pharmDx (SK006) can help identify patients for treatment with KEYTRUDA^1,2

• Worldwide, there were over 600,000 cases of esophageal cancer diagnosed in 2020³ and, in Europe, this type of cancer caused more than 45,000 deaths the same year ⁴
• PD-L1 testing provides a direct assessment of PD-L1 expression, which is a biomarker for response to anti-PD-1 therapy in esophageal cancer^1,2
• PD-L1 testing with PD-L1 IHC 22C3 pharmDx was used to assess PD-L1 expression in patients with locally advanced unresectable or metastatic esophageal cancer in the KEYNOTE-590 clinical trial^1,2

When confidence in a PD-L1 test is critical, the ONE you choose is crucial

• The ONE PD-L1 assay used in KEYTRUDA clinical trials^1,2
• The ONE PD-L1 assay first launched with KEYTRUDA in every indication that requires PD-L1 testing^1,2
• The ONE PD-L1 assay trusted worldwide to test hundreds of thousands of patients for KEYTRUDA⁵